MENU
Showcases Stock ranks Forex

Sangamo Therapeutics (SGMO)
0.6702  0.046 (7.28%) 03-28 16:00
Open: 0.625 Pre. Close: 0.6247
High: 0.6733 Low: 0.62
Volume: 1,237,467 Market Cap: 136(M)
Stock Technical Analysis
Overall:     
Target: Six months: 1.22
One year: 1.54
Support: Support1: 0.59
Support2: 0.49
Resistance: Resistance1: 1.04
Resistance2: 1.32
Pivot: 0.78
Moving Averages: MA(5): 0.65
MA(20): 0.84
MA(100): 0.60
MA(250): 0.91
MACD: MACD(12,26): -0.06
Signal(12,26,9): -0.02
%K %D: %K(14,3): 10.02
%D(3): 4.85
RSI: RSI(14): 42.57
52-Week: High: 1.82
Low: 0.29
Change(%): -60.6
Average Vol(K): 3-Month: 2364
10-Days: 2600
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.671 - 0.674 0.674 - 0.677
Low: 0.612 - 0.616 0.616 - 0.619
Close: 0.664 - 0.67 0.67 - 0.676
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ SGMO ] has closed above bottom band by 24.8%. Bollinger Bands are 17.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Stock chart
Stock News
Fri, 29 Mar 2024
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Fri, 29 Mar 2024
Sangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62 - MarketBeat

Mon, 25 Mar 2024
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today - Yahoo Finance

Sat, 23 Mar 2024
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding - Simply Wall St

Sat, 16 Mar 2024
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24% - Simply Wall St

Wed, 13 Mar 2024
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Business Wire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 178.91
% Held by Insiders 163160000.00
% Held by Institutions 10.72
Shares Short (K) 9980
Shares Short Prior Month (K)
Stock Financials
EPS -87430000.000
Book Value (p.s.)
Profit Margin -146.30
Operating Margin -2.00
Return on Assets (ttm) 476.1
Return on Equity (ttm) -17.6
Qtrly Rev. Growth 176230000.0
Gross Profit (p.s.) -64.236
Sales Per Share -94.771
EBITDA (p.s.)
Qtrly Earnings Growth -1.48
Operating Cash Flow (M)
Levered Free Cash Flow (M) -224.84
Stock Valuation
PE Ratio
PEG Ratio 0.11
Price to Book value
Price to Sales -0.01
Price to Cash Flow 2.05
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 10060000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android